此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

The Neurobiology of Approach Avoidance Training in Depression (ACTIV8)

2017年8月31日 更新者:Charles Taylor、University of California, San Diego
The purpose of this study is to test the effects of a computerized approach/avoidance training (AAT) procedure on behavioral, affective, and brain mechanisms that are important for reward sensitivity and well-being in individuals diagnosed with major depression. The training procedure is designed to modify automatic approach responses for positive social stimuli. The primary aim is to determine the effects of approach/avoidance training on the functioning of brain systems during reward processing in individuals diagnosed with major depression. A secondary aim will determine whether brain activation patterns following approach/avoidance training predict subsequent affective and behavioral responses during reward processing. An exploratory aim will test whether completing the approach/avoidance training procedure in combination with a brief computer-delivered behavioral activation program for depression will produce larger changes in depression symptoms, positive emotions, and social relationship functioning from pre- to post-intervention compared to the control training procedure.

研究概览

研究类型

介入性

注册 (预期的)

40

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • California
      • San Diego、California、美国、92037-0855
        • University of California, San Diego; Psychiatry Clinical Research

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 55年 (成人)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Ages 18-55
  • Principal psychiatric diagnosis of major depressive disorder
  • Patient Health Questionnaire - 9 item score ≥ 10
  • Ability to read and speak English sufficiently to complete study procedures

Exclusion Criteria:

  • History of psychosis, mania, or substance dependence
  • Current severe medical disorder that requires inpatient treatment or frequent medical follow ups including but not limited to: unstable hypertension, unstable angina, unstable diabetes mellitus, unstable cardiac arrhythmias, transient ischemic attacks, sever coronary artery disease, sever peripheral vascular disease, severe hepato-gastro-intestinal disease, severe infectious disease (e.g. HIV), recurrent severe headache or migraine, fainting spells, seizures, and history of traumatic brain injury with loss of consciousness > 30 minutes
  • Current use of the following medications: antidepressants, benxodiazepines, antipsychotics, mood stabilizers, or other drugs that can acutely affect the hemodynamic response (methylphenidate and acetazolamide)
  • Caffeine intake > 10 cups/day or recent significant changes in consumption
  • MRI exclusions, including claustrophobia, cardiac pacemaker, metal fragments in eyes/skin/body (shrapnel), aortic/aneurysm clips, prosthesis, by-pass surgery/coronary artery clips, hearing aid, heart valve replacement, shunt (ventricular or spinal), electrodes, metal plates/pins/screws/wires, or neuro/bio-stimulators (TENS unit), persons who have ever been a metal worker/welder, history of eye surgery/eyes washed out because of metal, women who are or may be pregnant (determined by a positive pregnancy test), women using an intrauterine device, vision problems uncorrectable with lenses, inability to lie still on one's back for 60 minutes; prior neurosurgery; older tattoos with metal dyes; unwillingness to remove nose, ear, tongue or face rings.
  • Concurrent psychosocial treatment: Participants completing ongoing psychosocial treatment will be required to meet a 12-week stability criteria so that symptom changes as a result of other psychosocial treatments are not confounded with changes due to the research.
  • Inability to complete the initial assessment battery or behavioral training sessions.
  • Clinical conditions assessed by the interviewer that necessitate more imminent clinical care (e.g., active suicidal ideation). These criteria are in place so participants with these other, more several symptoms can be referred for appropriate mental health services.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:双倍的

武器和干预

参与者组/臂
干预/治疗
实验性的:Approach-positive AAT
Computerized AAT procedure designed to increase automatic approach responses for positive social cues.
One session of approach-positive AAT (Aim 1 and 2) followed by 4 sessions of approach-positive AAT over 2 weeks concurrent with a brief computer-delivered behavioral activation treatment for depression (Aim 3).
安慰剂比较:Control AAT
Computerized AAT procedure in which there is no contingency between arm movement and positive social cues.
One session of control-AAT (Aim 1 and 2) followed by 4 sessions of control-AAT over 2 weeks concurrent with a brief computer-delivered behavioral activation treatment for depression (Aim 3).

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Change from pre-training in blood oxygen level dependent (BOLD) response in the striatum, amygdala, and medial prefrontal cortex, as measured with functional magnetic resonance imaging (fMRI) during reward trials on the Social Incentive Delay (SID) task.
大体时间:Post-training (5 minutes)
Change from pre- to post-training in neural activation during social reward processing.
Post-training (5 minutes)

次要结果测量

结果测量
措施说明
大体时间
Response bias to rewards on the Probabilistic Reward Task (PRT)
大体时间:Post-training (20 minutes) and 1 month
Post-training (20 minutes; Aim 2) and post-AAT plus brief behavioral activation treatment (1 month; Aim 3) reward response bias on the PRT.
Post-training (20 minutes) and 1 month
Response to social interaction task
大体时间:Post-training (30 minutes) and 1 month
Post-training (30 minutes; Aim 2) and post-AAT plus brief behavioral activation treatment (1 month; Aim 3) behavioral and emotional response to the social interaction task.
Post-training (30 minutes) and 1 month

其他结果措施

结果测量
措施说明
大体时间
Change from baseline in depression (Patient Health Questionnaire-9; Beck Depression Inventory II, composite)
大体时间:1 month
Change from pre- to post-assessment following AAT plus brief behavioral activation treatment (Aim 3) in symptoms of depression.
1 month
Change from baseline in positive affect (Positive and Negative Affect Schedule)
大体时间:1 month
Change from pre- to post-assessment following AAT plus brief behavioral activation treatment (Aim 3) in positive affect.
1 month
Change from baseline in social relationship functioning (Social Connectedness Scale - Revised; Interpersonal Outcomes Scale)
大体时间:1 month
Change from pre- to post-assessment following AAT plus brief behavioral activation treatment (Aim 3) in social relationship functioning.
1 month
Change from baseline in anhedonia (Mood and Symptom Anxiety Questionnaire; Environmental Reward Observation Scale)
大体时间:1 month
Change from pre- to post-assessment following AAT plus brief behavioral activation treatment (Aim 3) in anhedonia.
1 month
Change from baseline in anxiety (State Trait Anxiety Inventory).
大体时间:1 month
Change from pre- to post-assessment following AAT plus brief behavioral activation treatment (Aim 3) in anxiety.
1 month

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2014年7月1日

初级完成 (实际的)

2017年4月1日

研究完成 (实际的)

2017年7月1日

研究注册日期

首次提交

2014年12月24日

首先提交符合 QC 标准的

2015年1月2日

首次发布 (估计)

2015年1月5日

研究记录更新

最后更新发布 (实际的)

2017年9月1日

上次提交的符合 QC 标准的更新

2017年8月31日

最后验证

2017年8月1日

更多信息

与本研究相关的术语

其他研究编号

  • 21695

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅